Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.211 (Moderna Inc)
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
mRNA-1273.211 is a bivalent mRNA-based COVID-19 vaccine booster developed by Moderna. It consists of a 1:1 ratio of mRNA-1273, which encodes the spike protein of the ancestral SARS-CoV-2 strain, and mRNA-1273.351, which encodes the spike protein of the Beta (B.1.351) variant. Delivered via PEGylated lipid nanoparticles (LNPs), the vaccine instructs host cells to produce these spike proteins, thereby eliciting a broad neutralizing antibody response and cellular immunity. It was designed to provide enhanced protection against emerging variants of concern and has been evaluated in Phase 2/3 clinical trials as a booster dose for individuals who previously completed a primary vaccination series of the original mRNA-1273 vaccine.
- Other names
- Moderna bivalent COVID-19 vaccine (ancestral/Beta)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1273.211 (Moderna Inc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.211 (Moderna Inc).